Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases
US10882855B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 10, 2019 |
| Grant date | Jan 5, 2021 |
| Priority date | — |
| Expiry date | May 10, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.